Traders are feeling more bearish on shares of the company recently if you watch the increase in short interest. The company realized a rise in short interest of 10.61% between September 29, 2017 and October 13, 2017. Short shares grew 368,129 over that timeframe. With short interest at 3,837,573 and short average daily volume at 347,629, the short-interest ratio is 11.0 and the short interest percentage is 0.26% as of October 13.
Additionally, here are a few investment firms who have increased or decreased their stake in (EGRX). Blair William & Co/il reduced its position by selling 7,460 shares a decrease of 9.4% in the quarter. Blair William & Co/il currently owns 71,575 shares worth $4,269,000. The value of the position overall is down by 31.5%. Lazard Asset Management LLC expanded its investment by buying 73,565 shares an increase of 26.5% from 06/30/2017 to 09/30/2017. Lazard Asset Management LLC owns 351,673 shares with a value of $20,973,000. The total value of its holdings decreased 4.4%.
Raymond James & Associates bolstered its ownership by buying 1,704 shares an increase of 36.6% as of 09/30/2017. Raymond James & Associates controls 6,359 shares valued at $379,000. The value of the position overall is up by 3.3%. Baird Financial Group, Inc. trimmed its stake by shedding 170 shares a decrease of 0.5%. Baird Financial Group, Inc. now controls 33,717 shares with a value of $2,011,000. The value of the position overall is down by 24.8%.
On November 9 Royal Bank Of Canada maintained a stock rating of “Outperform” projecting a price of $75.00. November 8 investment analysts at Mizuho kept the stock rating at “Sell” with a current price target of $37.00.
On October 27 Piper Jaffray Companies left the stock rating at “Buy” targeting a price of $75.00. Mizuho lowered the price target on September 6 changing the price objective from $40.00 to $37.00 with a rating of “Underperform”.
Piper Jaffray Companies released research on EGRX with a rating of “Buy” and a price target of $75.00. Equity analyst Royal Bank Of Canada lowered the price target of the stock on July 27 cutting the projection from $94.00 to $81.00 and stated a “Outperform” rating.
The company is up from yesterday’s close of 55.16. The P/E ratio is 9.02 and market capitalization is 835.61M. As of the latest earnings report the EPS was $6.21 with 14.92M shares presently outstanding.
Eagle Pharmaceuticals, Inc., launched on January 2, 2007, is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Business’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin’s lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Its bendamustine product is a lyophilized powder that requires reconstitution in water prior to use. The EP-3101 RTD and Bendeka liquid formulations eliminate the need to reconstitute the drug prior to use, relative to the lyophilized presentation of Treanda..